Advertisement
Screener

AGENUS INC (AGEN) Revenues

2.8 / 5 stars · 68/120 Roast Me

AGENUS INC Revenues

AGENUS INC (AGEN) reported Revenues of $1.64 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.

Discontinued › Income Statement

us-gaap:Revenues · last filed 2018-05-10

  • AGENUS INC revenues for the quarter ending 2018-03-31 was $1.64M, a 93.93% decline year-over-year.
  • AGENUS INC revenues for the quarter ending 2017-12-31 was $8.35M, a 49.82% increase year-over-year.
  • AGENUS INC revenues for the quarter ending 2017-09-30 was $3.36M, a 24.45% decline year-over-year.
  • AGENUS INC revenues for the quarter ending 2017-06-30 was $4.21M, a 36.17% decline year-over-year.
  • AGENUS INC revenues for fiscal 2017 was $42.88M, a 89.95% increase from fiscal 2016.
  • AGENUS INC revenues for fiscal 2016 was $22.57M, a 9.04% decline from fiscal 2015.
  • AGENUS INC revenues for fiscal 2015 was $24.82M, a 255.67% increase from fiscal 2014.
  • AGENUS INC revenues for fiscal 2014 was $6.98M, a 129.13% increase from fiscal 2013.
Period endRevenues 3 monthRevenues 3 month as first filedRevenues 6 monthRevenues 9 monthRevenues 12 month
2018-03-31$1.64M
10-Q · filed 2018-05-10
$9.99M
derived: sum of 2 quarters · filed 2018-05-10
$13.35M
derived: sum of 3 quarters · filed 2018-05-10
$17.56M
derived: sum of 4 quarters · filed 2018-05-10
2017-12-31$8.35M
10-K · filed 2018-03-16
$11.71M
derived: sum of 2 quarters · filed 2018-03-16
$15.92M
derived: sum of 3 quarters · filed 2018-03-16
$42.88M
10-K · filed 2018-03-16
2017-09-30$3.36M
10-K · filed 2018-03-16
$3.36M
10-Q · filed 2017-11-07
$7.57M
derived: sum of 2 quarters · filed 2018-03-16
$34.52M
10-Q · filed 2017-11-07
$40.10M
derived: sum of 4 quarters · filed 2018-05-10
2017-06-30$4.21M
10-K · filed 2018-03-16
$4.21M
10-Q · filed 2017-08-07
$31.16M
10-Q · filed 2017-08-07
$36.74M
derived: sum of 3 quarters · filed 2018-05-10
$41.19M
derived: sum of 4 quarters · filed 2018-05-10
2017-03-31$26.96M
10-Q · filed 2018-05-10
$32.53M
derived: sum of 2 quarters · filed 2018-05-10
$36.98M
derived: sum of 3 quarters · filed 2018-05-10
$43.57M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$5.58M
10-K · filed 2018-03-16
$10.02M
derived: sum of 2 quarters · filed 2018-03-16
$16.61M
derived: sum of 3 quarters · filed 2018-03-16
$22.57M
10-K · filed 2018-03-16
2016-09-30$4.45M
10-K · filed 2018-03-16
$4.45M
10-Q · filed 2016-11-09
$11.04M
derived: sum of 2 quarters · filed 2018-03-16
$17.00M
10-Q · filed 2017-11-07
$24.64M
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30$6.59M
10-K · filed 2018-03-16
$6.59M
10-Q · filed 2016-08-04
$12.55M
10-Q · filed 2017-08-07
$20.19M
derived: sum of 3 quarters · filed 2018-03-16
$27.04M
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31$5.96M
10-K · filed 2018-03-16
$5.96M
10-Q · filed 2016-05-09
$13.60M
derived: sum of 2 quarters · filed 2018-03-16
$20.45M
derived: sum of 3 quarters · filed 2018-03-16
$26.82M
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31$7.64M
10-K · filed 2017-03-16
$14.49M
derived: sum of 2 quarters · filed 2017-03-16
$20.86M
derived: sum of 3 quarters · filed 2017-03-16
$24.82M
10-K · filed 2018-03-16
2015-09-30$6.85M
10-K · filed 2017-03-16
$6.85M
10-Q · filed 2015-11-04
$13.22M
derived: sum of 2 quarters · filed 2017-03-16
$17.18M
10-Q · filed 2016-11-09
$18.80M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$6.38M
10-K · filed 2017-03-16
$6.38M
10-Q · filed 2015-08-03
$10.33M
10-Q · filed 2016-08-04
$11.95M
derived: sum of 3 quarters · filed 2017-03-16
$13.51M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$3.95M
10-K · filed 2017-03-16
$3.95M
10-Q · filed 2015-05-01
$5.57M
derived: sum of 2 quarters · filed 2017-03-16
$7.13M
derived: sum of 3 quarters · filed 2017-03-16
$10.21M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$1.62M
10-K · filed 2016-03-15
$3.18M
derived: sum of 2 quarters · filed 2016-03-15
$6.26M
derived: sum of 3 quarters · filed 2016-03-15
$6.98M
10-K · filed 2017-03-16
2014-09-30$1.56M
10-K · filed 2016-03-15
$1.56M
10-Q · filed 2014-10-31
$4.64M
derived: sum of 2 quarters · filed 2016-03-15
$5.36M
10-Q · filed 2015-11-04
$5.75M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$3.07M
10-K · filed 2016-03-15
$3.07M
10-Q · filed 2014-08-01
$3.79M
10-Q · filed 2015-08-03
$4.19M
derived: sum of 3 quarters · filed 2016-03-15
$4.92M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$721.00K
10-K · filed 2016-03-15
$720.86K
10-Q · filed 2014-05-09
$1.11M
derived: sum of 2 quarters · filed 2016-03-15
$1.85M
derived: sum of 3 quarters · filed 2016-03-15
$2.66M
derived: sum of 4 quarters · filed 2016-03-15
2013-12-31$393.00K
10-K · filed 2015-03-16
$1.13M
derived: sum of 2 quarters · filed 2015-03-16
$1.94M
derived: sum of 3 quarters · filed 2015-03-16
$3.05M
10-K · filed 2016-03-15
2013-09-30$736.00K
10-K · filed 2015-03-16
$735.99K
10-Q · filed 2013-11-08
$1.54M
derived: sum of 2 quarters · filed 2015-03-16
$2.65M
10-Q · filed 2014-10-31
$3.74M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30$807.00K
10-K · filed 2015-03-16
$807.40K
10-Q · filed 2013-08-09
$1.92M
10-Q · filed 2014-08-01
$3.01M
derived: sum of 3 quarters · filed 2015-03-16
$3.88M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31$1.11M
10-K · filed 2015-03-16
$1.11M
10-Q · filed 2013-05-10
$2.20M
derived: sum of 2 quarters · filed 2015-03-16
$3.07M
derived: sum of 3 quarters · filed 2015-03-16
$3.69M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31$1.09M
10-K · filed 2014-03-07
$1.96M
derived: sum of 2 quarters · filed 2014-03-07
$2.59M
derived: sum of 3 quarters · filed 2014-03-07
$15.96M
10-K · filed 2015-03-16
2012-09-30$869.00K
10-K · filed 2014-03-07
$868.80K
10-Q · filed 2012-11-07
$1.50M
derived: sum of 2 quarters · filed 2014-03-07
$14.87M
10-Q · filed 2013-11-08
$15.52M
derived: sum of 4 quarters · filed 2014-03-07
2012-06-30$627.00K
10-K · filed 2014-03-07
$626.79K
10-Q · filed 2012-08-08
$14.00M
10-Q · filed 2013-08-09
$14.65M
derived: sum of 3 quarters · filed 2014-03-07
$15.30M
derived: sum of 4 quarters · filed 2014-03-07
2012-03-31$13.38M
10-K · filed 2014-03-07
$13.37M
10-Q · filed 2012-05-09
$14.02M
derived: sum of 2 quarters · filed 2014-03-07
$14.67M
derived: sum of 3 quarters · filed 2014-03-07
$15.46M
derived: sum of 4 quarters · filed 2014-03-07
2011-12-31$644.00K
10-K · filed 2013-03-18
$1.30M
derived: sum of 2 quarters · filed 2013-03-18
$2.08M
derived: sum of 3 quarters · filed 2013-03-18
$2.76M
10-K · filed 2014-03-07
2011-09-30$654.00K
10-K · filed 2013-03-18
$653.68K
10-Q · filed 2011-11-04
$1.44M
derived: sum of 2 quarters · filed 2013-03-18
$2.11M
10-Q · filed 2012-11-07
$3.11M
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30$786.00K
10-K · filed 2013-03-18
$786.43K
10-Q · filed 2011-08-05
$1.46M
10-Q · filed 2012-08-08
$2.45M
derived: sum of 3 quarters · filed 2013-03-18
$3.08M
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31$672.00K
10-K · filed 2013-03-18
$671.88K
10-Q · filed 2012-05-09
$1.67M
derived: sum of 2 quarters · filed 2013-03-18
$2.29M
derived: sum of 3 quarters · filed 2013-03-18
$3.10M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$993.56K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$1.62M
derived: sum of 2 quarters · filed 2013-03-18
$2.42M
derived: sum of 3 quarters · filed 2013-03-18
$3.36M
10-K · filed 2013-03-18
2010-09-30$624.45K
10-Q · filed 2011-11-04
$1.43M
derived: sum of 2 quarters · filed 2011-11-04
$2.37M
10-Q · filed 2011-11-04
2010-06-30$805.17K
10-Q · filed 2011-08-05
$1.74M
10-Q · filed 2011-08-05
2009-12-31$3.33M
10-K · filed 2012-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
Surrozen, Inc./DE (SRZN)United States$0.395B
Zura Bio Ltd (ZURA)$0.398B-6.56
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Ocugen, Inc. (OCGN)United States$0.343B-6.34
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60